© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Cancer Network spoke with Anna F. Farago, MD, of Massachusetts General Hospital, about the effect of trilaciclib on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan.
Cancer Network spoke with Anna F. Farago, MD, medical oncologist at Massachusetts General Hospital, about the effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan. The results (abstract 8505) were presented at ASCO 2019.
Related Content: